NCT02973997 - Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

August 15, 2022

Study Completion Date

October 8, 2023

Conditions

Columnar Cell Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaMetastatic Thyroid Gland Follicular CarcinomaMetastatic Thyroid Gland Papillary CarcinomaPoorly Differentiated Thyroid Gland CarcinomaRecurrent Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland Follicular CarcinomaRecurrent Thyroid Gland Papillary CarcinomaStage III Differentiated Thyroid Gland Carcinoma AJCC v7Stage III Thyroid Gland Follicular Carcinoma AJCC v7Stage III Thyroid Gland Papillary Carcinoma AJCC v7Stage IV Thyroid Gland Follicular Carcinoma AJCC v7Stage IV Thyroid Gland Papillary Carcinoma AJCC v7Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7Tall Cell Variant Thyroid Gland Papillary CarcinomaThyroid Gland Hurthle Cell CarcinomaUnresectable Differentiated Thyroid Gland CarcinomaUnresectable Thyroid Gland Carcinoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenvatinib

Given PO

DRUG

Lenvatinib Mesylate

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

43210

Ohio State University Comprehensive Cancer Center, Columbus

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

77030

M D Anderson Cancer Center, Houston

80045

University of Colorado Hospital, Aurora

90502

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER